Last reviewed · How we verify

Medeor Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Medeor Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
MDR-101 MDR-101 phase 3 Gene therapy ABCA3 gene Pulmonology / Rare Genetic Lung Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abeona Therapeutics, Inc · 1 shared drug class
  2. AskBio Inc · 1 shared drug class
  3. BioLab 612 LLC · 1 shared drug class
  4. Brain Neurotherapy Bio, Inc. · 1 shared drug class
  5. Emily de los Reyes · 1 shared drug class
  6. Eva Morava-Kozicz · 1 shared drug class
  7. Kolon TissueGene, Inc. · 1 shared drug class
  8. 4D Molecular Therapeutics · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Medeor Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Medeor Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medeor-therapeutics-inc. Accessed 2026-05-16.

Related